ARWR

Business Context and Reporting Period

Company: Arrowhead Pharmaceuticals, Inc. (ARWR)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Nine months ended June 30, 2025 (Fiscal Year 2025)
Business Overview: Arrowhead develops RNA interference (RNAi) therapeutics to treat intractable diseases by silencing disease-causing genes. The company operates research facilities in California and Wisconsin and maintains a pipeline of candidates in cardiometabolic, pulmonary, liver, neuromuscular, and CNS therapeutic areas.

Key Financial Metrics

Note: Debt figures represent the Credit Facility balance (current and long-term). The company also holds a liability related to the sale of future royalties which is accounted for as debt.

Material Changes vs. Prior Period

• Revenue Surge: Revenue for the nine months ended June 30, 2025, increased to $573.0 million from $3.6 million in the prior year period. This was driven primarily by the recognition of $570.3 million in revenue from the Sarepta Collaboration Agreement, including an upfront payment and equity premium.
• Profitability Shift: The company reported a net income of $22.1 million for the nine months ended June 30, 2025, compared to a net loss of $429.0 million in the same period of 2024. This turnaround was due to the significant revenue recognition from the Sarepta deal, partially offset by increased operating expenses.
• Operating Expenses: Research and Development (R&D) expenses increased by 17% ($62.4 million) year-over-year for the nine-month period, driven by the progression of clinical candidates and increased manufacturing costs. General and Administrative (G&A) expenses increased by 19% ($13.9 million), largely due to professional services related to commercialization preparations.
• Liquidity Improvement: Total cash and investments increased by approximately $219.4 million during the period, fueled by the Sarepta upfront payment ($500 million) and equity investment ($325 million), partially offset by debt repayments ($201.6 million) and operating expenses.
• Debt Reduction: The company repaid $201.6 million of its Credit Facility during the period, reducing the outstanding balance significantly compared to the prior year-end.

Guidance, Outlook, and Risks

• Strategic Developments:
  • Sarepta Collaboration: Closed a global licensing agreement for multiple neuromuscular and CNS programs. The company received $500 million upfront and $325 million in equity. Future milestones could total up to $10 billion.
  • Sanofi/Visirna Deal: Signed an asset purchase agreement to sell rights to plozasiran in Greater China to Sanofi for an upfront payment of $130 million and potential milestones up to $265 million.
  • Clinical Milestones: Triggered a $100 million milestone from Sarepta for ARO-DM1 enrollment (July 2025). Completed enrollment for Phase 3 trials of plozasiran (SHASTA-3, SHASTA-4, MUIR-3). Initiated Phase 3 YOSEMITE trial for zodasiran.
• Liquidity Outlook: Management expects sufficient liquidity to fund operations for at least the next 12 months based on current cash, investments, and operating plans.
• Risks and Contingencies:
  • Regulatory Risk: The FDA has accepted the New Drug Application (NDA) for plozasiran with a PDUFA date of November 18, 2025. Approval is not guaranteed.
  • Debt Covenants: The Credit Facility requires maintaining liquidity of at least $100 million if market cap exceeds $1.5 billion. It also includes mandatory prepayments and a Multiple of Invested Capital (MOIC) payment requirement upon early repayment.
  • Development Risk: Success depends on the progression of clinical trials and the achievement of regulatory milestones, which are subject to uncertainty.

Key Facts for Investor Verification

• Sarepta Revenue Recognition: Verify the accounting treatment of the $570.3 million revenue recognized from the Sarepta deal, specifically the allocation between upfront payments, equity premiums, and performance obligations.
• Debt Structure and Covenants: Review the terms of the Sixth Street Credit Facility, specifically the MOIC payment obligations and mandatory prepayment triggers linked to asset sales or milestones.
• Plozasiran Regulatory Status: Monitor the FDA's decision on the plozasiran NDA (PDUFA date: November 18, 2025) and the status of the Sanofi asset purchase agreement closing.
• Cash Burn vs. Milestone Inflows: Assess the sustainability of the cash position given the high R&D spend ($432.5 million for nine months) against the timing of future milestone payments from Sarepta, Sanofi, and other partners.
• Stock-Based Compensation: Note the significant non-cash stock-based compensation expense ($44.3 million for nine months) and its impact on future cash flow projections.